Drug Trial Radar · NCT07863635
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Oct 9, 2026
Primary completion
Dec 11, 2026
Study completion Dec 11, 2026
Sponsor
- Lead sponsor
- ModernaTX, Inc.Moderna (MRNA)
- Sponsor type
- Industry
- First posted
- Oct 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the immunogenicity and safety of mRNA-1283 and mRNA-1273 (variant formulations) within the current epidemiological environment
Conditions
- SARS-CoV-2
Interventions
mRNA-1273Biological
Sterile liquid for injection
mRNA-1283Biological
Sterile liquid for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Geometric Mean Titer (GMT) of Neutralizing Antibody (nAb) Against Vaccine-matched Variant FormulationTime frame: Day 29
- Geometric Mean Fold Rise (GMFR) of Neutralizing Antibody (nAb) Against Vaccine-matched Variant FormulationTime frame: Day 29
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Delricht Research @ Overland
Overland Park, Kansas · Recruiting
Delricht Research @ Louisville
Louisville, Kentucky · Recruiting
Delricht Research @ Charlotte
Charlotte, North Carolina · Recruiting
Delricht Research @ Magnolia Family Medicine
Hendersonville, Tennessee · Recruiting
Delricht Research @ Zomnir Family Medicine
Prosper, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.